Table 1.
Effects of subchronic adult CBDV administration on the RNA expression of plasticity and inflammatory brain markers (Study 1).
| Brain Region | Brain Marker | SUBCHRONIC TREATMENT AT ADULTHOOD | ||||||
|---|---|---|---|---|---|---|---|---|
| VEH | CBDV-20 | CBDV-100 | Significant Differences | |||||
| WT | KO | WT | KO | WT | KO | |||
| CA1 | BDNF | 1.00 ± 0.03 | 1.01 ± 0.02 | 0.99 ± 0.05 | 0.98 ± 0.03 | 0.93 ± 0.03 | 0.96 ± 0.04 | |
| IL-10 | 1.18 ± 0.23 | 1.11 ± 0.21 | 1.57 ± 0.44 | 1.16 ± 0.24 | 0.65 ± 0.12 | 0.82 ± 0.15 | ||
| IL-1β | 1.03 ± 0.10 | 0.95 ± 0.10 | 0.86 ± 0.07 | 1.09 ± 0.12 | 1.00 ± 0.07 | 1.14 ± 0.21 | ||
| IL-6 | 1.02 ± 0.08 | 1.05 ± 0.13 | 1.33 ± 0.22 | 1.10 ± 0.24 | 0.93 ± 0.13 | 0.95 ± 0.10 | ||
| CD11b | 1.00 ± 0.02 | 1.00 ± 0.02 | 1.12 ± 0.04 | 0.95 ± 0.04 | 1.05 ± 0.04 | 1.04 ± 0.07 | ||
| CD45 | 1.00 ± 0.03 | 0.95 ± 0.05 | 0.92 ± 0.05 | 0.88 ± 0.03 | 0.95 ± 0.06 | 1.00 ± 0.07 | ||
| TNF-α | 1.11 ± 0.18 | 0.91 ± 0.21 | 1.12 ± 0.15 | 0.84 ± 0.12 | 1.13 ± 0.20 | 1.04 ± 0.20 | ||
| CA3 | BDNF | 1.01 ± 0.04 | 1.10 ± 0.04 | 1.06 ± 0.06 | 1.04 ± 0.04 | 1.06 ± 0.06 | 1.03 ± 0.04 | |
| IL-10 | 1.13 ± 0.20 | 0.92 ± 0.23 | 1.07 ± 0.22 | 0.82 ± 0.16 | 1.58 ± 0.67 | 0.96 ± 0.14 | ||
| IL-1β | 1.14 ± 0.19 | 1.28 ± 0.25 | 0.94 ± 0.14 | 1.28 ± 0.25 | 2.37 ± 0.46 | 1.46 ± 0.26 | Treatment effect (CBDV-100 > CBDV-20 and VEH) only in WT | |
| IL-6 | 1.06 ± 0.12 | 0.59 ± 0.08 | 1.07 ± 0.18 | 1.19 ± 0.18 | 0.91 ± 0.22 | 0.90 ± 0.10 | ||
| CD11b | 1.01 ± 0.06 | 0.92 ± 0.05 | 1.05 ± 0.10 | 0.97 ± 0.04 | 0.89 ± 0.04 | 0.99 ± 0.06 | ||
| CD45 | 1.03 ± 0.09 | 0.92 ± 0.07 | 0.87 ± 0.06 | 1.07 ± 0.07 | 1.14 ± 0.08 | 1.26 ± 0.06 | Overall treatment effect (CBDV-100 > CBDV-20 and VEH) | |
| TNF-α | 1.06 ± 0.13 | 0.41 ± 0.04 | 1.03 ± 0.26 | 0.69 ± 0.16 | 0.86 ± 0.19 | 0.76 ± 0.09 | Overall genotype effect (KO < WT) | |
| DG | BDNF | 1.00 ± 0.03 | 1.24 ± 0.08 | 1.15 ± 0.06 | 1.11 ± 0.06 | 1.14 ± 0.04 | 1.18 ± 0.02 | Genotype effect (KO > WT) only in VEH |
| IL-10 | 1.10 ± 0.18 | 1.05 ± 0.19 | 1.03 ± 0.30 | 1.00 ± 0.19 | 0.82 ± 0.15 | 0.74 ± 0.14 | ||
| IL-1β | 1.03 ± 0.10 | 1.22 ± 0.22 | 1.53 ± 0.23 | 1.01 ± 0.06 | 1.45 ± 0.35 | 0.72 ± 0.06 | ||
| IL-6 | 1.17 ± 0.24 | 1.19 ± 0.12 | 1.30 ± 0.28 | 1.16 ± 0.13 | 1.14 ± 0.16 | 0.94 ± 0.08 | ||
| CD11b | 1.01 ± 0.06 | 1.04 ± 0.02 | 1.10 ± 0.05 | 1.02 ± 0.04 | 1.23 ± 0.10 | 1.06 ± 0.05 | ||
| CD45 | 1.02 ± 0.08 | 1.19 ± 0.09 | 1.14 ± 0.06 | 0.93 ± 0.09 | 1.23 ± 0.14 | 1.08 ± 0.07 | ||
| TNF-α | 1.06 ± 0.13 | 1.04 ± 0.19 | 0.92 ± 0.19 | 0.55 ± 0.08 | 0.72 ± 0.11 | 0.78 ± 0.21 | ||
| PFC | BDNF | 1.01 ± 0.04 | 0.95 ± 0.07 | 0.94 ± 0.10 | 0.91 ± 0.09 | 0.95 ± 0.06 | 0.92 ± 0.06 | |
| IL-10 | 0.93 ± 0.25 | 0.57 ± 0.04 | 1.44 ± 0.37 | 0.92 ± 0.18 | 0.64 ± 0.09 | 1.44 ± 0.39 | ||
| IL-1β | 1.05 ± 0.09 | 0.96 ± 0.13 | 1.20 ± 0.16 | 0.98 ± 0.09 | 0.86 ± 0.11 | 0.99 ± 0.08 | ||
| IL-6 | 0.83 ± 0.11 | 0.95 ± 0.20 | 1.33 ± 0.24 | 1.06 ± 0.11 | 0.90 ± 0.09 | 1.14 ± 0.14 | ||
| CD11b | 1.01 ± 0.06 | 0.98 ± 0.11 | 0.97 ± 0.06 | 0.91 ± 0.05 | 0.93 ± 0.07 | 1.03 ± 0.04 | ||
| CD45 | 0.55 ± 0.21 | 1.06 ± 0.11 | 0.95 ± 0.15 | 0.80 ± 0.03 | 1.05 ± 0.07 | 1.01 ± 0.08 | ||
| TNF-α | 0.56 ± 0.21 | 0.54 ± 0.13 | 0.68 ± 0.23 | 0.60 ± 0.12 | 0.59 ± 0.05 | 0.90 ± 0.16 | ||
mRNA quantification was performed by RT-qPCR analysis. The relative level of expression was calculated with the comparative (2−ΔΔCT) method [51]. Data refer to bold change and are expressed as mean ± SEM. Sample size for each group was 7–9. Statistically significant differences are highlighted in yellow. CA1 = hippocampal CA1 subfield; CA3 = hippocampal CA3 subfield; DG = dentate gyrus; PFC = prefrontal cortex.